California’s economy now tops US$4.5 trillion in output, which underlines how quickly well positioned businesses can scale when conditions line up. For investors, that raises a simple question: Which financially solid companies might still be early in their earnings growth journey? This article focuses on a group of firms where analysts expect profit expansion over the next three years and highlights three standouts from that growth focused list.
The stocks covered below are just a small sample, since the full healthy high growth potential screen surfaced 1,574 more companies with equally compelling stories that are not included here. To see the broader opportunity set, head straight into the Healthy high growth potential screener to identify, filter, and analyze the ideas that best fit your own conviction and risk tolerance.
Broadcom (AVGO)
Overview: Broadcom is a global digital infrastructure supplier, providing AI focused data center semiconductors alongside infrastructure software for networking, storage, and security.
Operations: Broadcom generates about US$59.4b from Semiconductor Solutions and around US$29.7b from Infrastructure Software, reflecting a balanced hardware software mix.
Market Cap: US$1.7t
Broadcom matters for this Healthy high growth potential screen because its AI focused networking and custom chips are directly linked to earnings expansion, while a sizable software arm is part of a broad digital infrastructure platform.
"Broadcom is generating substantial free cash flow, expanding its custom silicon business, strengthening its position in networking, and integrating software assets that further diversify earnings."
The key variable is how one concentrated stream of AI driven demand ultimately feeds through to pricing power, contract terms, and margin durability.
That is where the real story starts, and the full narrative for Broadcom shows how Broadcom’s cash generation, AI demand and software mix could interact or decouple over time.
Amylyx Pharmaceuticals (AMLX)
Overview: Amylyx Pharmaceuticals develops clinical-stage therapies for neurodegenerative and endocrine conditions, with late-stage drug candidates that anchor its growth-focused story.
Market Cap: US$3.5b
Amylyx Pharmaceuticals matters for this Healthy high growth potential screen because its neurodegeneration-focused pipeline ties future earnings directly to a small number of pivotal trial outcomes over the next few years.
"Advancement of avexitide as a potential first approved therapy for post bariatric hypoglycemia, supported by five prior PBH trials and a fully recruited pivotal Phase III LUCIDITY study with top line data expected in Q3 2026, could open a new rare disease revenue stream if outcomes support approval and reimbursement."
The key question is how one unresolved piece of the story ultimately shapes pricing power, adoption curves, and the timing of any earnings inflection.
That turning point is exactly what the full narrative for Amylyx Pharmaceuticals unpacks, separating trial risk from what accelerating success could mean for Amylyx Pharmaceuticals beyond the next data readout.
Micron Technology (MU)
Overview: Micron Technology designs and manufactures memory and storage chips that power AI data centers, PCs, smartphones, vehicles, and industrial systems worldwide.
Market Cap: US$1.2t
Micron Technology matters for this Healthy high growth potential screen because its cloud and core data-center memory products are central to analyst expectations for strong earnings growth tied to AI and server demand over the next few years.
"High bandwidth memory is stacked DRAM designed to feed AI accelerators with enough bandwidth to keep them busy. It is more complex, more valuable, and more capacity-hungry than conventional DRAM."
What happens to Micron Technology’s growth story depends heavily on how one concentrated source of AI-driven demand shapes pricing and margin power.
That concentration of demand is exactly what the full narrative for Micron Technology unpacks, mapping how AI acceleration, pricing cycles, and downside risks could reshape Micron Technology’s earnings story.
Curious About What You Might Be Missing?
Fresh opportunities do not sit still. Breakout stories gain momentum, quiet compounders fly once the crowd catches on, and under the radar for now quickly becomes crowded. Act now.
- Spot resilient cash generators before they get re rated by using the curated list of solid balance sheet and fundamentals (25 results) that filters for quality first and noise second.
- Ride secular shifts in automation by scanning the hand picked 89 robotics and automation stocks packed with businesses tied to real world robots, sensors, and intelligent machinery.
- Position ahead of the next infrastructure wave by reviewing the focused 39 power grid technology and infrastructure stocks featuring companies wired into grid upgrades, reliability, and electrification.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com